Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Preclinical studies demonstrate antitumor activity and HIF-1alpha inhibition for ENMD-1198
November 10th, 2005
EntreMed, Inc., (ENMD), a clinical-stage pharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, announced positive preclinical results for ENMD-1198, an analog of 2-methoxyestradiol (2ME2). The data were presented by EntreMed scientists during an oral presentation at the International Tumor Metabolism Summit held in Genova, Italy. Oral administration of ENMD-1198 showed pronounced in vivo antitumor activity in preclinical models of human cancer. Oral daily treatment with ENMD-1198 in an orthotopic MDA MB 231 breast cancer model led to the disruption of microtubules within tumor cells and a...
Source: Women's Health Weekly (2005-11-10)
|
